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IL-17 producing T helper (TH17) cells have recently been identiﬁed as a new subset involved in the
pathogenesis of various autoimmune diseases. Exogenous factors promoting TH17 induction have
been intensely characterized, whereas the T cell-intrinsic mechanisms inﬂuencing TH17 develop-
ment are less established. The transcription factor RORct, which belongs to the nuclear receptor
superfamily, serves as master transcription factor essential for TH17 differentiation, whereas other
members of the nuclear receptor family control TH17 differentiation and contribute to protection
from TH17-mediated autoimmunity. In this review, we will highlight the most recent understand-
ings about the regulatory function of nuclear receptors during TH17 cell differentiation.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. TH17 cells and autoimmunity
T helper (TH) cells play a central role in initiating and maintain-
ing a broad range of immune responses. The ﬁrst subtypes that
have been characterized are TH1 cells and TH2 cells [1]. TH1 cells
predominantly produce interferon (IFN)c and lymphotoxin; these
cells are involved in host defence against intracellular pathogens
and in recruitment of macrophages to the sites of infection, but
also in induction of delayed-type hypersensitivity responses. TH2
cells, characterized by cytokines such as interleukin (IL)-4, IL-5
and IL-13, have been shown to be essential for immunity against
extracellular organisms such as parasites and helminths. Moreover,
they play an important role during allergic reactions.
In the last years, a third subset named TH17 cells has been iden-
tiﬁed that is characterized by production of IL-17A, IL-17F, IL-21,
IL-22, and IL-23R [2]. These cells seem to play a specialized role
during host defence against distinct pathogens such as Citrobacter,
Borrelia burgdorferi, Klebsiella pneumoniae or Candida albicans,
which are not adequately controlled by TH1 or TH2 cells [3]. During
the last years, TH17 cells have also been implicated in the develop-
ment of autoimmune diseases, such as multiple sclerosis (MS),
rheumatoid arthritis and inﬂammatory bowel disease [4]. The cru-
cial role of TH17 cells for development of central nervous system
(CNS) autoimmunity has ﬁrst been demonstrated by Cua et al.cal Societies. Published by Elsevier
tz).who showed that lack of IL-23, which is essential for expansion
and maintenance of TH17 cells in vivo, renders mice completely
resistant to experimental autoimmune encephalomyelitis (EAE),
the animal model of MS [5]. In humans, several studies addressed
the role of TH17 cells in MS, and documented pronounced IL-17
expression in active areas of MS lesions [6,7], and in mononuclear
cells from blood and cerebrospinal ﬂuid of MS patients, which
strongly correlated with disease activity [8]. Studies in mice have
shown that TH17 cells play a critical role both in induction and pro-
gression of EAE [9,10]. However, it is still unclear what accounts for
the particular pathogenicity of these cells, as the master cytokines
IL-17A and IL-17F do not substantially inﬂuence the disease course
of EAE [11]. TH17 cells originate under distinct polarizing condi-
tions; they depend on the presence of transforming growth factor
(TGF)b together with proinﬂammatory cytokines such as IL-6 or IL-
21 in mice [9,12], and IL-1b, or IL-23 in humans [13,14]. Although
the conditions favoring TH17 induction and expansion have been
intensely investigated, less information exists on the molecular
mechanisms that control TH17 differentiation and hence protect
from TH17-mediated autoimmunity.
2. The nuclear receptor family: General features
The nuclear receptor (NR) family plays a role in a broad spec-
trum of functions such as development, metabolism and homeo-
stasis, but also immune regulation and inﬂammation [15,16].B.V. Open access under CC BY-NC-ND license.
Table 1
Protective effects of NR in TH17-mediated autoimmunity.
Receptor Ligands investigated
(example)
Autoimmune
disease
models
Proposed
mechanism(s) on T cell
differentiation
AHR Dioxin 2-(10H-indole-
30carbonyl)-thiazole-4-
carboxylic acid methyl
ester (ITE) b-
naphthoﬂavone (bNF)
leﬂunomide
EAE [24,25],
colitis [26]
Sustained increase in
STAT-1 signalling;
during T cell
differentiation;
induction of STAT-5;
Treg induction
RARs All-trans retinoic acid
(ATRA); 9-cis RA
Am580; Am80
EAE [20],
arthritis [27],
colitis [28],
LE [29]
Inhibition of RORct
expression; FoxP3
induction
PPARs Pioglitazone,
rosiglitazone, 15d-PGJ2
(PPARc) fenoﬁbrate
(PPARa) GW0742
(PPARd)
EAE30,
arthritis [18],
colitis [31]
transrepression of
RORct transcription;
induction of PPARc
expression
LXRs T0901317 GW3965
oxysterols
EAE [32],
arthritis [33],
LE [34]
induction of Srebp-1
with resulting
inhibition of RORct
and IL-17 transcription
Vitamin
D
1a,25-
Dihydroxyvitamin D(3)
TX527
EAE [35],
arthritis [36],
colitis [36],
LE [37]
inhibition of TH17
differentiation and
induction of IL-10
producing T cells
in vivo
GR Steroids; 2-(4-
acetoxyphenyl)-2-
chloro-N-methylethyl-
ammoniumchloride
(CpdA)
EAE [38],
arthritis [39],
colitis [40]
inhibition of TH17
differentiation in vivo;
induction of T cell
apoptosis
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extracellular or intracellular signals into a transcriptional response,
either by activating or repressing gene expression. In humans, the
family consists of 48 members [17]. NRs are deﬁned by common
structural motifs which are highly conserved and consist of three
major domains: a highly variable NH3-terminal ligand-indepen-
dent activation domain (AF-1), a central DNA-binding domain
(DBD), which targets the receptor to speciﬁc DNA sequences called
hormone response elements (HRE), and a carboxy-terminal ligand
binding domain responsible for receptor dimerization, ligand rec-
ognition and cofactor interaction [17]. NR can be divided into three
broad classes. Receptors of the ﬁrst class are classical endocrine
receptors that are usually cytoplasmic and translocate into the nu-
cleus upon ligand binding. Prominent examples are the glucocorti-
coid hormone receptor (GR), the vitamin D receptor (VDR), and the
aryl hydrocarbon receptor (AHR). The second class consists of a
group of ‘‘adopted orphan receptors’’, for which ligands have been
identiﬁed after characterization of the receptors and which form
heterodimers with the nuclear receptor retinoid X receptor
(RXR). Members of this group are the retinoic acid receptors
(RAR), the liver X receptors (LXR), and the peroxisome prolifera-
tor-activated receptors (PPARs). The third class contains a heterog-
enous group of receptors termed ‘‘true’’ orphan receptors, for
which endogenous ligands are not yet identiﬁed, and crystal struc-
ture analysis suggested that at least some are most likely not reg-
ulated by ligands based on the size of their ligand binding pocket.
Mechanistically, it has been shown that ligand binding to NR –
especially those of the second class such as PPARs and LXRs – in-
duces a distinct conformational change resulting in dissociation
of corepressor molecules and association with large coactivator-
complexes. Subsequently, these receptor complexes can bind to
speciﬁc response elements located in the promoter region of target
genes and turn on gene transcription [17]. This mechanism is in-
volved in mediation of metabolic effects such as adipocyte differ-
entiation, fatty acid oxidation and glucose metabolism. However,
during the last years, NR has also been identiﬁed as important reg-
ulators of inﬂammatory signalling both during innate and adaptive
immune responses [16]. Interestingly, the molecular mechanisms
of NR-mediated anti-inﬂammatory effects clearly differ from those
of metabolic effects: For LXR and PPARc it has been shown that li-
gand-induced conformational changes allow SUMOylation of the
receptor, which then binds to and stabilizes co-repressor com-
plexes at the promoters of proinﬂammatory genes, thus interfering
with gene transcription under inﬂammatory conditions. This
mechanism, which is termed nuclear receptor-mediated transre-
pression has been identiﬁed as crucial for mediation of immune-
regulatory effects by NR in macrophages [18,19], and will therefore
not be discussed here in detail.
3. Nuclear receptors and autoimmunity
A connection between ligand-activation of NR and control of T
cell-mediated autoimmunity has long been postulated, as several li-
gands such as retinoic acid, vitamin D, and several PPARc agonists
have been shown to be protective in several models of T cell-
mediated autoimmunity such as EAE, experimental colitis, and
collagen-induced arthritis (Table 1) [18,20–22].Moreover, large epi-
demiologic studies indicated that alterations in vitamin D levels are
associated with increased autoimmunity [23]. However, the target
cell populations of these ligand-mediated effects and the exact
mechanisms of action have not been elucidated until recently.
4. The nuclear receptor RORct determines TH17 differentiation
The ﬁrst clear molecular implication for a role of NR in TH cell
differentiation comes from the observation that a member of theretinoic acid related orphan receptor subfamily, i.e. RORct, has
been identiﬁed as the master transcription factor essential for
the differentiation of naive CD4+ T cells into TH17 cells both in
the murine and in the human system [9]. Expression of this
transcription factor in T cells depends on the presence of
cytokine-mediated signals, e.g. the combination of TGFb and proin-
ﬂammatory cytokines such as IL-6 [12]. The fact that retrovirus-
mediated overexpression of RORct in CD4+ T cells is at least
in vitro sufﬁcient for induction of TH17 differentiation suggests
that the activity of this nuclear receptor does not depend on the
presence of a speciﬁc ligand. In fact, a ligand for RORct has not
been identiﬁed so far. However, it can be imagined that RORct
may be activated by a yet unidentiﬁed, ubiquitously present li-
gand. Additionally, the related receptor RORa is sufﬁcient but not
essential for TH17 differentiation [13].
5. Modulation of TH17 differentiation by nuclear receptors5.1. RARa
Interestingly, ligand-activation of RARa, a receptor closely re-
lated to RORct, has been shown to strongly interfere with TH17 dif-
ferentiation (and also with TH1 and TH2 differentiation), indicating
that even closely related NR are involved in a complex and even
opposing cell-intrinsic regulation of T cell differentiation [41,42].
Activation of RARa by all-trans-retinoic-acid (ATRA) not only sup-
presses differentiation of TH17 cells, but reciprocally facilitates
differentiation into functional regulatory T cells (Tregs) expressing
the transcription factor forkhead box protein 3 (FoxP3). Mechanisti-
cally, it has been shown that RARa activation by ATRA strongly sup-
presses RORct expression and simultaneously induces FoxP3;
however, the exact molecular mechanisms how RARa represses
RORct function and hence RORct-mediated TH17 differentiation
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iated induction of FoxP3 may be responsible for the suppressive ef-
fect on TH17 cell generation, as FoxP3 can inhibit RORct function via
direct interaction [43,44]. Due to early postnatal lethality of RARa-
deﬁcient mice, tissue-speciﬁc deletion strategies will be necessary
to further evaluate the role of RARa for control of TH17 differentia-
tion. It is important to note, however, that RARa agonists directly
act on T cells, as the effects do not require the presence of antigen-
presenting dendritic cells, and the effects on TH17 differentiation
can be mimicked by retroviral overexpression of RARa in T cells
[45]. However, in vivo, it is feasible that RARa ligands are produced
by distinct dendritic cell subsets in relevant quantities to inﬂuence
the direction of T cell differentiation in a paracrine fashion. In the
gut, for instance, DCs located in the gut-associated lymphatic tissue
are able to synthesize ATRA from dietary beta-carotene [46]. It has
therefore been proposed that the immuno-protective milieu of the
gut may be shaped by the relatively high concentrations of vitamin
A metabolites in this organ, a hypothesis that is supported by the
observation that prevalence of TH17 cells in the gut is limited in spite
of high local IL-6 concentrations.
5.2. AHR
The AHR is involved in the T cell-intrinsic regulation of TH17 dif-
ferentiation in a very complex and even conﬂicting manner, which
is not fully understood yet. This receptor has been identiﬁed about
30 years ago and binds a broad range of ligands including haloge-
nated aromatic hydrocarbons and non-halogenated polycyclic aro-
matic such as TCDD (2,3,7,8-tetrachlordibenzodioxin), known from
cigarette smoke and industrial contaminants [47]. Recently, it has
been observed that AHR is strongly expressed in TH17 cells but
not in other TH cell subsets [24,48]. Genetic ablation of the AHR
provided evidence that this receptor enhances TH17 development
and expansion of TH17 cells, hence promoting TH17-mediated
CNS autoimmunity. Although this receptor is not essential for gen-
eration of TH17 cells, it promotes further functional differentiation
and its expression is a prerequisite for production of the cytokine
IL-22 [49]. Activation of the AHR pathway in vivo is probably med-
iated by high-afﬁnity endogenous ligands such as 6-formylindo-
lo(3,2b) carbazole FICZ, a tryptophane metabolite [24]. However,
the toxic AHR ligand TCDD, which is also a high afﬁnity ligand
for AHR, instead induces Treg differentiation and suppresses both
TH17 cells and thus EAE development [48]. Moreover, another
endogenous AHR ligand induced tolerogenic dendritic cells that
promoted Treg differentiation in a retinoic acid-dependent manner
and suppressed EAE [25]. The reason for these opposing effects
mediated by different high afﬁnity AHR ligands are so far not
understood; it has been speculated that in the case of TCDD, due
to its high toxicity, the observed shift in T cell populations may
be due to the relatively high resistance of Tregs to toxic depletion
regiments [49]. The molecular mechanisms of AHR mediated mod-
ulation of T cell differentiation do not seem to be mediated by reg-
ulation of RORct activity [50], but instead involve direct
interference with STAT-1 (signal transducer and activator of tran-
scription-1) signaling, a negative regulator of TH17 differentiation.
Further analysis of AHR function in the context of TH17 differenti-
ation will be particular relevant for a better understanding of the
potential link between environmental factors and the development
of (auto)immunity, which has already been suspected for the AHR
ligand dioxin and rheumatoid arthritis, and for smoking and psori-
asis or rheumatoid arthritis [51,52].
5.3. PPARc
We recently identiﬁed the nuclear receptor PPARc as a cell-
intrinsic regulator of TH17 differentiation [30]. PPARc belongs tothe second group of NR and is best known for its complex effects
on glucose metabolism and adipocyte differentiation, and several
ligands are already in clinical use for the treatment of metabolic
disturbances in patients suffering from NIDDM. Its metabolic ef-
fects are mediated via transcriptional promoter activation by the
ligand-activated PPARc-RXR heterodimer. Due to its large binding
pocket, a broad range of endogenous and pharmacological ligands
have been identiﬁed such as unsaturated linoleic acid metabolites,
i.e. 9s-HODE (hydroxyoctadecadienoic acid) and 13s-HODE, 15d-
prostaglandin J2 (PGJ2), oxLDL, and the synthetic thiazolidinedi-
ones (e.g. Pioglitazone and Rosiglitazone) and several NSAIDs. So
far, a large number of PPARc-mediated anti-inﬂammatory effects
have been characterized; they involve negative regulation of mac-
rophage, dendritic cell, endothelial cell, but also B and T lympho-
cyte function [18]. The potential therapeutic implication of its
anti-inﬂammatory potential is reﬂected by the beneﬁcial effects
of pharmacological PPARc activation in several animal models of
autoimmunity and inﬂammation, such as EAE, inﬂammatory bowel
disease, allergic airway inﬂammation, experimental arthritis, and
carrageenan-induced pleurisy [18]. We observed that pharmaco-
logical PPARc activation selectively impairs differentiation into
TH17 cells, whereas differentiation of TH1 cells, TH2 cells and also
Tregs was not inﬂuenced by PPARc. By using conditional PPARc
knock-out mice which lack PPARc exclusively in the T cell com-
partment, we could prove that these effects were really mediated
by PPARc. It should be noted that PPARa does not inﬂuence TH17
cell generation, but instead enhances TH1 generation and sup-
presses development of TH2 cells [53]. PPARd, on the other hand,
suppresses production of a number of cytokines by activated T cells
including IL-17A and IFNc, but does not inﬂuence RORct activity
[54]. It can therefore be concluded that even closely related nuclear
receptors do not modulate T cell differentiation in a similar fash-
ion, but instead contribute to a complex network of NR-mediated
control of T cell differentiation.
6. Molecular mechanisms of PPARc-mediated control of TH17
differentiation
PPARc prevented cytokine-mediated de-novo expression of
RORct in T cells, which explains the selectivity of the effect, as
expression of T-bet and of GATA-3, the master transcription factors
for TH1 and TH2 differentiation, were not inﬂuenced by PPARc.
Mechanistically, a direct interaction of PPARc with the RORct pro-
moter was not observed. Instead, we found that prior to induction
of RORct transcription by TGFb and IL-6, the corepressor complex
SMRT (silencing mediator of retinoid and thyroid hormone recep-
tors) had to be removed from the RORct promoter, presumably
by ubiquitination and targeting to the proteasome. This step was
prevented in the presence of the PPARc agonist pioglitazone, indi-
cating that ligand-activated PPARc stabilized SMRT at the RORct
promoter hence preventing initiation of RORct transcription
(Fig. 1). These data not only reveal how PPARc controls TH17 dif-
ferentiation but provide evidence that transrepression mecha-
nisms are relevant for NR-mediated control of T cell function in
general.
Under non-inﬂammatory conditions, the co-repressor SMRT is
bound to the RORct promoter and inhibits transcription (left). Al-
ready 30 min after TH17 induction by TGFb and IL-6, the SMRT
co-repressor complex is rapidly removed from the promoter, and
RORct transcription starts (upper part). Unliganded PPARc does
not interact with SMRT. Upon ligand binding, PPARc undergoes a
conformational change, which permits interaction with SMRT
and results in stabilization of the corepressor complex at the RORct
promoter, thus preventing RORct transcription (lower part).
Detailed ﬂow cytometric analysis using T cells derived from
RORC-GFP reporter mice revealed that activation of PPARc during
Fig. 1. Schematic model of PPARc-mediated transrepression during TH17-differentiation.
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basis, i.e. it did not only alter the percentage of GFP positive cells,
but decreased mean RORct expression levels on a single-cell-basis.
It can therefore be concluded that PPARc ﬁne-tunes the receptive-
ness of T cells to signals in their microenvironment. In other words,
PPARc signalling during TH17 differentiation does not act in a bin-
ary way by switching the differentiation program from ‘‘on’’ to
‘‘off’’, but instead decreases the susceptibility of each T cell to
TH17 promoting conditions.
7. Role of endogenous PPARc ligands
The fact that TH17 differentiation and TH17-dependent immune
responses in vivo were augmented in T cell-speciﬁc PPARc knock-
out mice suggests that the PPARc pathway plays a relevant role in
the control of TH17 responses under physiological conditions. We
therefore assume that endogenous PPARc activity may be relevant
for protection from unrestrained TH17 induction in situations
where this is unfavourable, e.g. in autoimmunity. At this moment
we do not know whether these effects may be at least partly med-
iated by ligand-independent PPARc activity, or whether they are
mediated by endogenous ligands. The latter assumption, however,
is supported by the observation that ligand-activation was re-
quired for PPARc-mediated transrepression of the RORct pro-
moter. Moreover, endogenous agonists such as 13s-HODE were
very efﬁcient suppressors of TH17 differentiation, and this effect
clearly depended on PPARc expression in T cells.
It should be noticed that oral supplementation with precursors
of endogenous PPARc agonists such as linoleic acid protected from
autoimmune conditions such as EAE and colitis, and at least in the
latter case this was shown to be mediated via PPARc [31,55]. On
the other hand does ablation of the PPARc ligand-producing
enzyme 12/15 lipoxygenase (LOX) result in enhanced CNS autoim-
munity during EAE [56]. While these studies indicate that endoge-
nous PPARc agonists in vivo contribute to protection from
development of autoimmunity, it is not clear whether this is a di-
rect effect on T cells, or whether these ligands also modulate other
immune cells such as dendritic cells. Endogenous PPARc ligands
are produced by macrophages in physiologically relevant quanti-
ties [57]. The factors that elicit ligand production are largely un-
known; interestingly, it has been shown that the
immunomodulatory cytokine IL-4 strongly enhances PPARc ago-
nist production, suggesting that the well-known ‘‘protective’’ effect
of TH2 responses in CNS autoimmunity might at least in part be
mediated by induction of endogenous PPARc agonist production.In support of this hypothesis, it has been shown that IL-4 interferes
with TH17 differentiation by yet unknown mechanisms [58,59].
These data so far suggest that control of TH17 cell differentiation
by endogenous PPARc ligands ismostly relevant in a paracrineman-
ner, with antigen-presenting cells asmajormodulators of T cell sen-
sitivity towards TH17 inducing conditions. However, expression of
12/15 lipoxygenase has also been observed in T cells themselves
(own unpublished observation); it can therefore be imagined that
T cells might control their own propensity towards TH17 differenti-
ation by autocrine supply of endogenous PPARc ligands. Taken to-
gether, thorough characterization of the cellular sources of
endogenous PPARc ligands and of the conditions favoring their pro-
duction will be an important task to further understand the physio-
logical relevance of PPARc-mediated control of TH17 differentiation
and TH17-mediated autoimmunity. Moreover, enhancement of
endogenous PPARc ligand productionmay provide a new therapeu-
tic strategy for limiting TH17-mediated autoimmunity.
8. Modulation of PPARc expression levels
Our data employing PPARcKO T cells indicate that the sensitivity
of T cells to local TH17-inducing conditions also depends on PPARc
expression levels, as a reduction of PPARc levels in T cells will
enhance their sensitivity to TH17 inducing conditions, whereas
high PPARc levels would interfere with TH17 differentiation.
Accordingly, CNS autoimmunity was shown to be augmented in
heterocygous PPARc knock-out mice, which corroborates the
hypothesis that PPARc expression levels inﬂuence the propensity
to autoimmune responses [60]. In humans, we observed a strong
decrease in PPARc expression levels in PBMCs of MS patients in
comparison to healthy controls, which suggests that there might
exist a link between inﬂammation-induced loss of PPARc expres-
sion and enhanced sensitivity to autoimmunity. On the other hand,
ligand activation of PPARc in vitro prevented inﬂammation-in-
duced loss of PPARc expression in PBMCs, and long-term treatment
with PPARc agonists in vivo also protected from inﬂammation-in-
duced loss of PPARc expression [61]. Furthermore, it has been
shown that synthetic PPARc ligands induce expression of their
own receptor by increasing PPARc gene transcription [62]. Hence,
PPARc ligands not only result in receptor activation, but also in-
crease receptor expression and protect from inﬂammation-induced
loss of PPARc. PPARc activation thus provides a positive autoregu-
latory feedback-loop that protects from desensitization towards
NR-mediated control of TH17 cell differentiation. From a therapeu-
tic point of view, the correlation between inﬂammatory stimula-
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important conclusions: First, employing PPARc agonists as acute
treatment during full-blown autoimmune reactions does not seem
to be a feasible approach, as their receptor-activating capacity will
be limited due to decreased receptor expression. Second, strong
proinﬂammatory stimulation, e.g. in case of an infection, will per-
mit efﬁcient adaptive immunity, as the concomitant decrease in
PPARc expression levels will interrupt the regulatory signalling
cascade that limits the propensity of T cells to differentiate into
TH17 cells. This conclusion is supported by the fact that long-term
treatment with high-afﬁnity PPARc ligands does not result in
strong immunosuppression, albeit the rate of upper respiratory
infections is slightly increased in these patients [63,64].
8.1. LXRa/b
The liver X receptors (LXR), which are known for their meta-
bolic effects on cholesterol homeostasis, have also been implicated
in the control of T cell proliferation and TH17 differentiation
[32,65]. Three years ago, Bensinger et al. could directly link the
metabolic properties of LXRb in T cells, i.e. modulation of the oxy-
sterol-metabolizing enzyme SULT2B1 (sulfotransferase family
cytosolic 2B member 1), to alterations of acquired immune re-
sponses, which represents the ﬁrst demonstration of NR-mediated
metabolic effects with a direct impact on the immune system. Fol-
lowing this line, it has very recently been shown that LXRa and b in
T cells both interfere with TH17 differentiation and hence restricted
TH17-mediated autoimmunity during EAE [47]. In T cells, LXRs in-
duced SREBP-1 (sterol regulatory element-binding protein-1),
which translocated into the nucleus and inhibited AHR activity at
the IL-17 promoter through direct physical interaction. These ﬁnd-
ings allow several important conclusions: First, NR-mediated met-
abolic effects may be relevant for their inﬂuence on T cell
functions. Second, NR-mediated effects on T cell differentiation
do not only involve repression mechanisms, but are in part medi-
ated by gene activation. And third, different NR-induced pathways
in T cells may interfere with each other, as in this case LXR and
AHR, thus adding to the complexity of NR-mediated modulation
of TH17 differentiation.
9. Concluding remarks
So far, a number of NR has been shown to be intensely involved
in the regulation of TH17 differentiation and TH17-mediated auto-
immunity. Some of them induce or enhance TH17 differentiation
such as RORct, RORa and AHR, whereas some of them interfere
with TH17 differentiation, e.g. RARa, PPARc, and LXRa/b. Several
independent molecular mechanisms have been implicated in NR-
mediated control of T cell differentiation. As illustrated by PPARc,
a prominent feature of NR-mediated regulation is a ﬁne-tuning of
the sensitivity of T cells towards TH17-inducing conditions; in
other words, NR alter the threshold which determines whether a
naïve T cell becomes a TH17 cell or not. The distinct pattern of
NR expression within the T cell thus contributes to regulation of
T cell differentiation, which implies that not only exogenous fac-
tors such as the speciﬁc local cytokine milieu but also T cell-intrin-
sic factors decide about the fate of a T cell during differentiation. At
the moment it is completely unclear whether NR also contribute to
the known enormous plasticity of TH17 cells [66,67], which has
been observed in vivo. It is conceivable that NR not only decide
about TH17 differentiation, but also control whether differentiated
T cells maintain their TH17 phenotype or may de-differentiate.
Moreover, it still has to be addressed whether NR also alter the
functional properties of TH17 cells, especially during autoimmu-
nity. Deliberate modulation of the expression pattern of NR as wellas enhancement of NR activity in T cells –either by addition of
exogenous agonists or by induction of endogenous ligand produc-
tion – will help to further elucidate the function of this important
receptor family during TH17 differentiation and may provide new
avenues for treatment of TH17-dependent autoimmunity.
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